Primary cutaneous cryptococcus in a patient with multiple sclerosis treated with fingolimod

JAMA Neurology

Volumn 73, Issue 3, 2016, Pages 355-356

  Forrestel, Amy K ^a   Modi, Badri G ^a   Longworth, Sarah ^a   Wilck, Marissa B ^a   Micheletti, Robert G ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FINGOLIMOD; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT;

ADULT; CASE REPORT; CRYPTOCOCCUS NEOFORMANS; CUTANEOUS CRYPTOCOCCOSIS; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FOREHEAD; GIANT CELL; GRANULOMATOUS INFLAMMATION; HISTIOCYTE; HUMAN; HUMAN TISSUE; LETTER; LOADING DRUG DOSE; LYMPHOCYTE; MIDDLE AGED; MULTIPLE SCLEROSIS; NONHUMAN; PRIMARY CUTANEOUS CRYPTOCOCCOSIS; PRIORITY JOURNAL; SKIN BIOPSY; SKIN NODULE; CRYPTOCOCCOSIS; ISOLATION AND PURIFICATION; PATHOGENICITY; WOUND INFECTION;

CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FEMALE; FINGOLIMOD HYDROCHLORIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; MULTIPLE SCLEROSIS; WOUND INFECTION;

EID: 84961725584     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2015.4259     Document Type: Letter

References (6)

1. Mehling M, Brinkmann V, Antel J, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology. 2008;71(16):1261-1267.
2. Mehling M, Hilbert P, Fritz S, et al. Antigen-specific adaptive immune responses in fingolimod-Treated multiple sclerosis patients. Ann Neurol. 2011;69 (2):408-413.
3. Francis G, Kappos L, O'Connor P, et al. Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Mult Scler. 2014;20 (4):471-480.
4. Arvin AM, Wolinsky JS, Kappos L, et al. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol. 2015;72(1):31-39.
5. Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(6):545-556.
6. Neuville S, Dromer F, Morin O, Dupont B, Ronin O, Lortholary O; French Cryptococcosis Study Group. Primary cutaneous cryptococcosis: A distinct clinical entity. Clin Infect Dis. 2003;36(3):337-347.